Citations

Showing 10 of 108104 citations.

Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
Quick, Allison , Hundley, Andrew F., Evans, Cynthia, Stephens, Julie , Ramaswamy, Bhuvaneswari , Reinbolt, Raquel E. , Deusen, Jeffrey Bryan Van, Williams, Nicole , Sardesai, Sagar , Loprinzi, Charles L. , Lustberg, Maryam B. , Quick, Allison M , Lustberg, Maryam , Noonan, Anne M. , Deusen, Jeff Van, Wesolowski, Robert , Stover, Daniel G. , Faubion, Stephanie S.

Mayo Clinic

Journal of Clinical Medicine | January 31, 2022 | Volume: 11 | Issue: 3 | Pages: 774

10.3390/jcm11030774 | PMID 35160226 Get It

(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO2 laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO2 laser therapy and returned for a 4 week follow-up. Participants were contacted for follow-up at annual intervals. The Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Female Sexual Distress Scare Revised (FSDS-R), the Urinary Distress Inventory (UDI), and adverse events were collected and reported for the two-year follow-up. The changes in scores were compared between the four-week and two-year and the one-year and two-year follow-ups using paired t-tests. (3) Results: In total, 67 BC survivors were enrolled, 59 completed treatments and the four week follow-up, 39 participated in the one-year follow-up, and 33 participated in the two-year follow-up. After initial improvement in the VAS from baseline to the four week follow-up, there was no statistically significant difference in the VAS score (mean Δ 0.23; 95% CI [−0.05, 0.51], p = 0.150) between the four week follow-up and the two-year follow-up. At the two-year follow-up, the FSFI and FSDS-R scores remained improved from baseline and there was no statistically significant change in the FSFI score (mean Δ −0.83; 95% CI [−3.07, 2.38] p = 0.794) or the FSDS-R score (mean Δ −2.85; 95% CI [−1.88, 7.59] p = 0.227) from the one to two-year follow-up. The UDI scores approached baseline at the two-year follow-up; however, the change between the one- and two-year follow-ups was not statistically significant (mean Δ 4.76; 95% CI [−1.89, 11.41], p = 0.15). (4) Conclusions: Breast cancer survivors treated with fractional CO2 laser therapy have sustained improvement in sexual function two years after treatment completion, suggesting potential long-term benefit.
Diagnostic Performance of Pancreatic Cytology with the Papanicolaou Society of Cytopathology System: A Systematic Review, before Shifting into the Upcoming WHO International System
Nikas, Ilias P. , Proctor, Tanja, Seide, Svenja , Chatziioannou, Stylianos Sergios , Reynolds, Jordan , Ntourakis, Dimitrios , Reynolds, Jordan P

Mayo Clinic

International Journal of Molecular Sciences | January 31, 2022 | Volume: 23 | Issue: 3 | Pages: 1650

10.3390/ijms23031650 | PMID 35163571 Get It

The Papanicolaou Society of Cytopathology (PSC) reporting system classifies pancreatobiliary samples into six categories (I–VI), providing guidance for personalized management. As the World Health Organization (WHO) has been preparing an updated reporting system for pancreatobiliary cytopathology, this systematic review aimed to evaluate the risk of malignancy (ROM) of each PSC category, also the sensitivity and specificity of pancreatic FNA cytology using the current PSC system. Five databases were investigated with a predefined search algorithm. Inclusion and exclusion criteria were applied to select the eligible studies for subsequent data extraction. A study quality assessment was also performed. Eight studies were included in the qualitative analysis. The ROM of the PSC categories I, II, III, IV, V, VI were in the ranges of 8–50%, 0–40%, 28–100%, 0–31%, 82–100%, and 97–100%, respectively. Notably, the ROM IVB (“neoplastic—benign”) subcategory showed a 0% ROM. Four of the included studies reported separately the ROMs for the IVO subcategory (“neoplastic—other”; its overall ROM ranged from 0 to 34%) with low (LGA) and high-grade atypia (HGA). ROM for LGA ranged from 4.3 to 19%, whereas ROM for HGA from 64 to 95.2%. When the subcategory IVO with HGA was considered as cytologically positive, together with the categories V and VI, there was a higher sensitivity of pancreatic cytology, at minimal expense of the specificity. Evidence suggests the proposed WHO international system changes—shifting the IVB entities into the “benign/negative for malignancy” category and establishing two new categories, the “pancreatic neoplasm, low-risk/grade” and “pancreatic neoplasm, high-risk/grade”—could stratify pancreatic neoplasms more effectively than the current PSC system.
Outcomes of primary total hip arthroplasty following septic arthritis of the hip
Bettencourt, Jacob W. , Osmon, Douglas R. , Hanssen, Arlen D. , Berry, Daniel J. , Wyles, Cody C. , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 31, 2022 | Volume: 104-B | Issue: 2 | Pages: 227-234

10.1302/0301-620x.104b2.bjj-2021-1209.r1 | PMID 35094571 Get It

Aims Septic arthritis of the hip often leads to irreversible osteoarthritis (OA) and the requirement for total hip arthroplasty (THA). The aim of this study was to report the mid-term risk of any infection, periprosthetic joint infection (PJI), aseptic revision, and reoperation in patients with a past history of septic arthritis who underwent THA, compared with a control group of patients who underwent THA for OA. Methods We retrospectively identified 256 THAs in 244 patients following septic arthritis of the native hip, which were undertaken between 1969 and 2016 at a single institution. Each case was matched 1:1, based on age, sex, BMI, and year of surgery, to a primary THA performed for OA. The mean age and BMI were 58 years (35 to 84) and 31 kg/m2 (18 to 48), respectively, and 100 (39%) were female. The mean follow-up was 11 years (2 to 39). Results The ten-year survival free of any infection was 91% and 99% in the septic arthritis and OA groups, respectively (hazard ratio (HR) = 13; p < 0.001). The survival free of PJI at ten years was 93% and 99% in the septic arthritis and OA groups, respectively (HR = 10; p = 0.002). There was a significantly higher rate of any infection at ten years when THA was undertaken within five years of the diagnosis of septic arthritis compared with those in whom THA was undertaken > five years after this diagnosis was made (14% vs 5%, respectively; HR = 3.1; p = 0.009), but there was no significant difference in ten-year survival free of aseptic revision (HR = 1.14; p = 0.485). The mean Harris Hip Scores at two and five years postoperatively were significantly lower in the septic arthritis group compared with the OA group (p = 0.001 for both). Conclusion There was a ten-fold increased risk of PJI in patients with a history of septic arthritis who underwent THA compared with those who underwent THA for OA with a ten-year cumulative incidence of 7%. The risk of any infection had a strong downward trend as the time interval between the diagnosis of septic arthritis and THA increased, highlighted by a 3.1-fold higher risk when THAs were performed within five years of the diagnosis being made. Cite this article: Bone Joint J 2022;104-B(2):227–234.
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, Juan Esteban , Ruíz-Patiño, Alejandro , Sotelo, Carolina , Zatarain-Barrón, Lucía, Jaller, Elvira , Rojas, Leonardo , Russo, Alessandro , Miguel‐Pérez, Diego de , Cardona, Andrés F. , Ruíz-Patiño, Alejandro , Cardona, Andrés F , de Miguel-Perez, Diego , Garcia-Robledo, Juan Esteban , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Rosell, Rafael , Arrieta, Óscar , Ordóñez‐Reyes, Camila , Rolfo, Christian

Mayo Clinic

Therapeutic Advances in Respiratory Disease | January 31, 2022 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/17534666211066064 | PMID 35098800 Get It

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.
The re-invention of the vascular neuroradiologist in the age of direct-to-consumer radiology applications
Brinjikji, Waleed

Mayo Clinic

Interventional Neuroradiology | January 31, 2022 | Volume: 28 | Issue: 1 | Pages: 7-8

10.1177/15910199221077754 | PMID 35098754 Get It

Keratin 7 and ERBB2 Negative Mammary Paget Disease Without an Underlying in Situ and Invasive Carcinoma
Ratiani, Mariam , Farooq, Ayesha , Jorns, Julie M. , Sheinin, Yuri

Mayo Clinic

International Journal of Surgical Pathology | January 31, 2022 | Volume: 30 | Issue: 5 | Pages: 590-592

10.1177/10668969221076550 | PMID 35098762 Get It

We report a unique case of a post-menopausal female who presented with a lesion on the areola. A biopsy of the lesion demonstrated a pagetoid intraepithelial neoplasm suggesting a differential diagnosis of mammary Paget disease and pagetoid Bowen disease. Excision of the lesion confirmed the diagnosis of mammary Paget disease with typical histological appearance. This case is extremely rare since both keratin 7 and ERBB2 were negative, and there was no evidence of underlying in situ or invasive carcinoma.
Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
Miller, Robert G. , Zhang, Rongzhen , Bracci, Paige M. , Azhir, Ari, Barohn, Richard J., Bedlack, Richard , Benatar, Michael , Cudkowicz, Merit , Kasarskis, Edward J. , Mitsumoto, Hiroshi , Manousakis, Georgios , Walk, David , Oskarsson, Björn , McGrath, Michael S. , McGrath, Michael S , Oskarsson, Björn , Bedlack, Richard S , Cudkowicz, Merit E , Walk, David , Berry, James D. , Shefner, Jeremy M.

Mayo Clinic

Muscle & Nerve | January 31, 2022 | Volume: 66 | Issue: 1 | Pages: 39-49

10.1002/mus.27511 | PMID 35098554 Get It

AbstractIntroduction/AimsALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those with higher levels of the plasma inflammatory marker C‐reactive protein (CRP) in phase 2A studies in ALS. Here, we evaluate the effects of NP001 in a phase 2B trial, and perform a post hoc analysis with combined data from the preceding phase 2A trial.MethodsThe phase 2B trial enrolled 138 participants within 3 y of symptom onset and with plasma hs‐CRP values >1.13 mg/L. They were randomized 1:1 to receive either placebo or NP001 for 6 mo. Change from baseline ALSFRS‐R scores was the primary efficacy endpoint. Secondary endpoints included vital capacity (VC) change from baseline and percentage of participants showing no decline of ALSFRS‐R score over 6 mo (non‐progressor).ResultsThe phase 2B study did not show significant differences between placebo and active treatment with respect to change in ALSFRS‐R scores, or VC. The drug was safe and well tolerated. A post hoc analysis identified a 40‐ to 65‐y‐old subset in which NP001‐treated patients demonstrated slower declines in ALSFRS‐R score by 36% and VC loss by 51% compared with placebo. A greater number of non‐progressors were NP001‐treated compared with placebo (p = .004).DiscussionAlthough the phase 2B trial failed to meet its primary endpoints, post hoc analyses identified a subgroup whose decline in ALSFRS‐R and VC scores were significantly slower than placebo. Further studies will be required to validate these findings.
Doulas, Racism, and Whiteness: How Birth Support Workers Process Advocacy towards Women of Color
Salinas, Juan L. , Salinas, Manisha , Kahn, Megan, Salinas, Juan L.

Mayo Clinic

Societies | January 31, 2022 | Volume: 12 | Issue: 1 | Pages: 19

10.3390/soc12010019 Get It

Systemic racism is embedded in healthcare settings and is linked to high maternal mortality rates for Black women in US Society. Doulas, or birth support workers, are uniquely positioned to advocate for women of color going through the birthing process, but little is understood on how doulas come to terms with race, racism, and whiteness in maternal healthcare settings. Using qualitative in-depth interviews with 11 doulas in northeast Florida, this research study found that doulas’ advocacy for maternal justice leads to an intersection with racial justice through their support of minority women clients. Doulas shared stories of racial injustice when they compared their white and Black client experiences, leading to shifting strategies to address racism in maternal healthcare settings. Doulas also grappled with their connection to whiteness through their own identities and interaction with white and minority clients. Many doulas shared a need for anti-racism training and recruitment of Black doulas to meet the needs of women of color going through the birthing process.
Primary Effusion Lymphoma: A Clinicopathologic Perspective
Gathers, Diamone, Galloway, Emily A., Kelemen, Katalin, Gathers, Diamone A , Gibson, Sarah E. , Rosenthal, Allison , Muñoz, Javier

Mayo Clinic

Cancers | January 31, 2022 | Volume: 14 | Issue: 3 | Pages: 722

10.3390/cancers14030722 | PMID 35158997 Get It

Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the peritoneum, pleural space, and the pericardium. PEL is associated with the presence of human herpesvirus 8 (HHV8), also called the Kaposi sarcoma-associated herpesvirus (KSHV), with some variability in transformation potential suggested by frequent coinfection with the Epstein-Barr virus (EBV) (~80%), although the nature of the oncogenesis is unclear. Most patients suffering with this disease are to some degree immunocompromised (e.g., Human immunodeficiency virus (HIV) infection or post-solid organ transplantation) and, even with aggressive treatment, prognosis remains poor. There is no definitive guideline for the treatment of PEL, although CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) are frequently prescribed and, given the rarity of this disease, therapeutic focus is being redirected to personalized and targeted approaches in the experimental realm. Current clinical trials include the combination of lenalidomide and rituximab into the EPOCH regimen and the treatment of individuals with relapsed/refractory EBV-associated disease with tabelecleucel.
Asymmetrical Primary Lateral Sclerosis Presenting as Corticobasal Syndrome
Nakamura, M. , Koga, Shunsuke , Murakami, Aya , Koga, Shunsuke , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | January 30, 2022 | Volume: 81 | Issue: 2 | Pages: 154-156

10.1093/jnen/nlab104 | PMID 35094073 Get It